Evidence map›Paper›PMID 40553390›Full record

ArticleActa diabetologica2025

Associations between MASLD phenotypes and the risk of carotid artery plaque: a cross-sectional study among railway workers.

Jia Pan, Honglian Zeng, Yongyan Song, Xiaoli Zhang, Zihang Wang, Lei Tang, Bo Xie, Rong Peng, Yuanyuan Zhou, Beizhong Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Acta diabetologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jia PanCentral Laboratory of Yongchuan Hospital, Chongqing Medical University, Chongqing, China.
Honglian ZengDepartment of Health Management Center, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
Yongyan SongDepartment of Central Laboratory, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
Xiaoli ZhangDepartment of Health Management Center, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
Zihang WangShuangliu District Center for Disease Control and Prevention, Chengdu, Sichuan, China.
Lei TangDepartment of Health Management Center, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
Bo XieGeneral Medicine of Yongchuan Hospital, Chongqing Medical University, Chongqing, China.
Rong PengDepartment of Health Management Center, Clinical Medical College and Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China.
Yuanyuan ZhouInstitute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, Sichuan, China.
Beizhong LiuCentral Laboratory of Yongchuan Hospital, Chongqing Medical University, Chongqing, China. liubeizhong@cqmu.edu.cn.ORCID http://orcid.org/0000-0001-8360-6646

Funding

Chengdu Medical Research Project 2022663Nanchong City Science and Technology Project 22SXQT0131
6 · The paper itself

Abstract

aimsCurrent evidence on the association between metabolic dysfunction-associated steatotic liver disease (MASLD) phenotypes to carotid artery plaque (CAP) remains limited. This study aims to investigate both the association and the potential mediating effects of MASLD phenotypes on the risk of CAP.

methodsIn this cross-sectional study, 8644 participants were categorized into five groups based on hepatic steatosis and cardiometabolic criteria: Non-hepatic steatosis, Dysglycemia-MASLD, Overweight-MASLD, Lean-MASLD, and other hepatic steatosis. Multivariable logistic regression analysis was conducted to evaluate the association between MASLD phenotypes and CAP. Mediation analyses were performed to evaluate the mediating effect of dysglycemia and body mass index (BMI) on the relationship between MASLD and CAP.

resultsThe Dysglycemia-MASLD group exhibited the highest prevalence of CAP of 26.28%, followed by the Lean-MASLD (18.55%) and Overweight-MASLD (14.39%) groups. After adjusting for covariates, Dysglycemia-MASLD patients had a significantly higher risk of CAP, with an OR of 1.599 (95% CI 1.348, 1.896). Notably, individuals under 45 in the Dysglycemia-MASLD and Lean-MASLD subgroups had more than a two-fold increased risk of CAP compared to the Non-hepatic steatosis group, with ORs of 2.393 (95% CI 1.660, 3.416) and 2.724 (95% CI 1.002, 6.221), respectively. Mediation analysis indicated that dysglycemia and BMI mediated 30.86% and 24.49% of the association of MASLD with CAP.

conclusionThe risk of developing CAP varies across MASLD phenotypes, with Dysglycemia-MASLD and Lean-MASLD patients exhibiting the highest risk. Therefore, personalized health management strategies are essential for different MASLD phenotypes.

Indexed as

Carotid Artery DiseasesFatty LiverPlaque, AtheroscleroticAdultBody Mass IndexCross-Sectional StudiesFemaleHumansMaleMiddle AgedPhenotypePrevalenceRisk FactorsCarotid artery plaqueMetabolic dysfunction-associated steatotic liver diseaseNonalcoholic fatty liver diseaseType 2 diabetes mellitus

Identifiers

PMID40553390

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.